A phase II study of saracatinib (AZD0530), a Src inhibitor,...

Lung Cancer 2015 / 07 Vol. 89; Iss. 1

A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies

Gubens, Matthew A., Burns, Matthew, Perkins, Susan M., Pedro-Salcedo, Melanie San, Althouse, Sandy K., Loehrer, Patrick J., Wakelee, Heather A.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
89
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/j.lungcan.2015.04.008
Date:
July, 2015
File:
PDF, 446 KB
english, 2015
Conversion to is in progress
Conversion to is failed